Evaluation in Biblical Proverbs: A Linguo-Cultural Study from a Systemic Functional Perspective

The aim of this study is to examine more closely the realizations of evaluation in Biblical proverbs and to explain the role of evaluation in the construction of communities of shared values. The research method used in analyzing the corpus of 425 Biblical proverbs identified by Wolfgang Mieder is the appraisal analysis of J.R. Martin and P.R.R.White in combination with the culturematic analysis of R. Petrova. On the basis of the results obtained conclusions are drawn concerning the indexical and evaluative characteristics of the proverb cultureme. It is argued that the axiological charge proverbs get in actual use as a result of the inherent act of evaluation is an indispensable part of their meaning

Evaluation in Biblical Proverbs: A Linguo-Cultural Study from a Systemic Functional Perspective

The aim of this study is to examine more closely the realizations of evaluation in Biblical proverbs and to explain the role of evaluation in the construction of communities of shared values. The research method used in analyzing the corpus of 425 Biblical proverbs identified by Wolfgang Mieder is the appraisal analysis of J.R. Martin and P.R.R.White in combination with the culturematic analysis of R. Petrova. On the basis of the results obtained conclusions are drawn concerning the indexical and evaluative characteristics of the proverb cultureme. It is argued that the axiological charge proverbs get in actual use as a result of the inherent act of evaluation is an indispensable part of their meaning

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Background: Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH. Methods: In this phase 2b, double-blind, randomized, placebo-controlled trial, patients with noncirrhotic, highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo once daily for 24 weeks. The primary end point was a decrease of at least 2 points in the SAF-A score (the activity part of the Steatosis, Activity, Fibrosis [SAF] scoring system that incorporates scores for ballooning and inflammation) without worsening of fibrosis; SAF-A scores range from 0 to 4, with higher scores indicating more-severe disease activity. Secondary end points included resolution of NASH and regression of fibrosis. Results: A total of 247 patients underwent randomization, of whom 103 (42%) had type 2 diabetes mellitus and 188 (76%) had significant (moderate) or advanced fibrosis. The percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher among those who received the 1200-mg dose, but not among those who received the 800-mg dose, of lanifibranor than among those who received placebo (1200-mg dose vs. placebo, 55% vs. 33%, P = 0.007; 800-mg dose vs. placebo, 48% vs. 33%, P = 0.07). The results favored both the 1200-mg and 800-mg doses of lanifibranor over placebo for resolution of NASH without worsening of fibrosis (49% and 39%, respectively, vs. 22%), improvement in fibrosis stage of at least 1 without worsening of NASH (48% and 34%, respectively, vs. 29%), and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% and 25%, respectively, vs. 9%). Liver enzyme levels decreased and the levels of the majority of lipid, inflammatory, and fibrosis biomarkers improved in the lanifibranor groups. The dropout rate for adverse events was less than 5% and was similar across the trial groups. Diarrhea, nausea, peripheral edema, anemia, and weight gain occurred more frequently with lanifibranor than with placebo. Conclusions: In this phase 2b trial involving patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials. (Funded by Inventiva Pharma; NATIVE ClinicalTrials.gov number, NCT03008070.)

50 години Катедра „Социална медицина и организация на здравеопазването`

22 Май 201